Prospective Grant of Exclusive License: Human Anesthetic Formulation Based Upon Cyclodextrin Carriers, 20588-20589 [05-7850]

Download as PDF 20588 Federal Register / Vol. 70, No. 75 / Wednesday, April 20, 2005 / Notices Dated: April 12, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–7855 Filed 4–19–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, April 27, 2005, 1 p.m. to April 27, 2005, 2 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the Federal Register on April 7, 2005, 70 FR 17711. The meeting will be held April 28, 2005. The meeting time and location remain the same. The meeting is closed to the public. Dated: April 12, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–7856 Filed 4–19–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center For Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel, Epidemiology Member Conflict. Date: April 18, 2005. Time: 2:30 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. VerDate jul<14>2003 16:34 Apr 19, 2005 Jkt 205001 Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Sandra L. Melnick, DRPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3028D, MSC 7770, Bethesda, MD 20892, 301–435– 1251, melnicks@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Model Systems and Functional Genomics in Innate Immunity and Inflammation. Date: April 21, 2005. Time: 1:30 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Tina McIntyre, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4202, MSC 7812, Bethesda, MD 20892, 301–594– 6375, mcintyrt@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Regulation of Cytokine Production. Date: April 22, 2005. Time: 1:30 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Tina McIntyre, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4202, MSC 7812, Bethesda, MD 20892, 301–594– 6375, mcintyrt@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Second Primary Tumor Prevention Inhibitors in Head and Neck Cancer. Date: May 4, 2005. Time: 2:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Morris I. Kelsey, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6208, MSC 7804, Bethesda, MD 20892 301–435– 1718, kelseym@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: April 12, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–7857 Filed 4–19–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, April 6, 2005, 1:30 p.m. to April 6 2005, 2:30 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the Federal Register on March 30, 2005, 70 FR 16295–16296. The meeting will be held April 28, 2005, from 12:30 p.m. to 1:30 p.m. The meeting location remains the same. The meeting is closed to the public. Dated: April 12, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–7858 Filed 4–19–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Human Anesthetic Formulation Based Upon Cyclodextrin Carriers National Institutes of Health, Public Health Service, DHHS. ACTION: Notice. AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in U.S. Patent No. 6,407,079, entitled ‘‘Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation,’’ to Jurox Pty Ltd., having a place of business in Rutherford, Australia. The field of use may be limited to the development of injectable anesthetic formulations containing E:\FR\FM\20APN1.SGM 20APN1 Federal Register / Vol. 70, No. 75 / Wednesday, April 20, 2005 / Notices Alfaxalone-hydroxypropyl-beta cyclodextrin complex for use in humans. The United States of America has an interest in the patent rights of this invention. Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before July 19, 2005 will be considered. DATES: Requests for a copy of the patent, inquiries, comments and other materials relating to the contemplated license should be directed to: Pradeep Ghosh, J.D., Ph.D., M.B.A., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–5282; Facsimile: (301) 402–0220; e-mail: ghoshpr@mail.nih.gov. ADDRESSES: This technology relates to pharmaceutical compositions containing drugs that are instable or only sparingly soluble in water, and methods for their preparation. The compositions are characterized by increased water solubility and improved stability. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: Dated: April 11, 2005. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 05–7850 Filed 4–19–05; 8:45 am] BILLING CODE 4140–01–P VerDate jul<14>2003 16:34 Apr 19, 2005 Jkt 205001 DEPARTMENT OF HOMELAND SECURITY [Docket No. DHS–2005–0035] Border and Transportation Security Directorate Customs and Border Protection; Notice of Meeting of Departmental Advisory Committee on Commercial Operations of Customs and Border Protection and Related Functions (Commercial Operations Advisory Committee or COAC) Office of the Assistant Secretary, Border and Transportation Security, DHS. ACTION: Notice. AGENCY: SUMMARY: The Departmental Advisory Committee on Commercial Operations of Customs and Border Protection and Related Functions (Commercial Operations Advisory Committee or COAC) will meet in open session. This notice announces the date, time, and location for the second meeting of the ninth term, and the expected agenda for its consideration. DATES: The next meeting of the COAC will be held on Thursday, May 5, 2005, 9 a.m. to 1 p.m. ADDRESSES: The meeting will be held in The Ronald Reagan International Trade Center, Pavillion Room, 1300 Pennsylvania Avenue, NW., Washington, DC 20229, telephone (202) 344–1440; facsimile (202) 344–1969. FOR FURTHER INFORMATION CONTACT: Ms. Monica Frazier, Office of the Assistant Secretary for Border and Transportation Security, Department of Homeland Security, Washington, DC 20528, telephone (202) 282–8431; facsimile (202) 282–8504. SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the Federal Advisory Committee Act (FACA), Pub. L. 92–463, as amended (5 U.S.C. App.1 et seq.), the Omnibus Budget Reconciliation Act of 1987, Pub. L. 100– 203, Title IX, Section 9503(c), December 22, 1987, 100 Stat. 1330–381 (19 U.S.C. 2071 note), and under the Homeland Security Act of 2002, Pub. L. 107–297, November 26, 2002, 116 Stat. 2140, et seq. (6 U.S.C. 101, et seq.). Draft Agenda: The COAC is expected to pursue the following agenda, which may be modified prior to the meeting: 1. Update on Maritime Transportation Security Act (MTSA) Subcommittee Follow-up Items. 2. Update on Department of Homeland Security (DHS) Organization and Customs and Border Protection (CBP) Strategic Plan. 3. Update on Security Subcommittee. a. Customs-Trade Partnership Against Terrorism (C–TPAT) Process. PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 20589 b. Advance Cargo Information. c. World Customs Organization (WCO) Framework. 4. Update on Creation of Infrastructure Subcommittee. 5. Update on Broker Confidentiality. 6. Update on Achieving Paperless Entry for Apparel and Textiles. 7. Update on International Trade Data Systems (ITDS). 8. Automation Issues. a. Automated Commercial Environment (ACE) funding and development schedule. b. Automated Commercial System (ACS) downtime. 9. Food and Drug Administration (FDA) Bioterrorism Act. 10. Focused Assessment Program. 11. Committee Administration. Public Participation: You may submit comments, identified by DHS–____, by one of the following methods: • EPA Federal Partner EDOCKET Web Site: https://www.epa.gov/feddocket. Follow instructions for submitting comments on the Web site. • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. • E-mail: Monica.Frazier@dhs.gov When submitting comments electronically, please include DHS– ____in the subject line of the message. • Mail: Ms. Monica Frazier, Office of the Assistant Secretary for Border and Transportation Security, Department of Homeland Security, Washington, DC 20528, telephone (202) 282–8431; facsimile (202) 282–8504. To ensure proper handling, please reference DHS– ____on your correspondence. This mailing address may also be used for paper, disk, or CD–ROM submissions. • Hand Delivery/Courier: Ms. Monica Frazier, Office of the Assistant Secretary for Border and Transportation Security, Department of Homeland Security, Washington, DC 20528, telephone (202) 282–8431; facsimile (202) 282–8504. This meeting is open to the public; however, participation in COAC deliberations is limited to COAC members, Homeland Security and Treasury Department officials, and persons invited to attend the meeting for special presentations. Since seating is limited, all persons attending this meeting should provide notice preferably by 2 p.m. e.s.t. on Thursday, April 28, 2005, to Ms. Monica Frazier, Office of the Assistant Secretary for Border and Transportation Security, Department of Homeland Security, Washington, DC 20528, telephone (202) 282–8431; facsimile (202) 282–8504. Docket: For access to the docket to read background documents or comments received, go to https:// E:\FR\FM\20APN1.SGM 20APN1

Agencies

[Federal Register Volume 70, Number 75 (Wednesday, April 20, 2005)]
[Notices]
[Pages 20588-20589]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-7850]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Human Anesthetic 
Formulation Based Upon Cyclodextrin Carriers

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in 
U.S. Patent No. 6,407,079, entitled ``Pharmaceutical compositions 
containing drugs which are instable or sparingly soluble in water and 
methods for their preparation,'' to Jurox Pty Ltd., having a place of 
business in Rutherford, Australia. The field of use may be limited to 
the development of injectable anesthetic formulations containing

[[Page 20589]]

Alfaxalone-hydroxypropyl-beta cyclodextrin complex for use in humans. 
The United States of America has an interest in the patent rights of 
this invention.

DATES: Only written comments and/or application for a license, which 
are received by the NIH Office of Technology Transfer on or before July 
19, 2005 will be considered.

ADDRESSES: Requests for a copy of the patent, inquiries, comments and 
other materials relating to the contemplated license should be directed 
to: Pradeep Ghosh, J.D., Ph.D., M.B.A., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 435-5282; Facsimile: (301) 402-0220; e-mail: 
ghoshpr@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This technology relates to pharmaceutical 
compositions containing drugs that are instable or only sparingly 
soluble in water, and methods for their preparation. The compositions 
are characterized by increased water solubility and improved stability.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 90 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 11, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-7850 Filed 4-19-05; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.